Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: The prospective observational scoop trial results

C.D. Pepa, C. Cavaliere, S. Rossetti, M. Di Napoli, S.C. Cecere, A. Crispo, C. De Sangro, E. Rossi, D. Turitto, D. Germano, G. Iovane, M. Berretta, C. D'Aniello, S. Pisconti, L. Maiorino, B. Daniele, C. Gridelli, S. Pignata, G. Facchini

Research output: Contribution to journalArticle

Abstract

The Comprehensive Geriatric Assessment (CGA) represents the future of the geriatric oncology to reduce toxicities and treatment-related hospitalization in the elderly. Most patients receiving docetaxel for metastatic castration-resistant prostate cancer are in their seventies or older. We explored the efficacy of the CGA in predicting chemotherapy feasibility and response to docetaxel in a cohort of 24 patients aged at least 70. This was an observational, prospective study involving 24 patients who were 70 years of age or older and about to start chemotherapy with docetaxel for metastatic castration-resistant prostate cancer; we performed a CGA including five domains and divided our patients into 'healthy' and 'frail'; the relations between general condition and (i) early chemotherapy discontinuation and (ii) response to docetaxel were explored. We found a statistically significant relationship between frailty assessed by CGA and early docetaxel discontinuation; we also found an association between frailty and response to chemotherapy, but this did not reach statistical significance. A geriatric assessment before starting chemotherapy may help clinicians to recognize frail patients, and hence to reduce toxicities and early treatment discontinuation. Further analyses are required to simplify the CGA tools and to facilitate its incorporation into routine clinical practice. © Copyright 2016 Wolters Kluwer Health, Inc. All rights reserved.
Original languageEnglish
Pages (from-to)104-109
Number of pages6
JournalAnti-Cancer Drugs
Volume28
Issue number1
DOIs
Publication statusPublished - 2017

Keywords

  • Comprehensive Geriatric Assessment
  • Docetaxel
  • Elderly
  • Prostate cancer
  • abiraterone
  • cabazitaxel
  • cyclophosphamide
  • docetaxel
  • enzalutamide
  • ipilimumab
  • navelbine
  • antineoplastic agent
  • taxoid
  • adult
  • aged
  • Article
  • cancer chemotherapy
  • cancer patient
  • castration resistant prostate cancer
  • clinical article
  • clinical effectiveness
  • cohort analysis
  • controlled study
  • Cumulative Illness Rating Scale for Geriatrics
  • geriatric assessment
  • Geriatric Depression Scale
  • human
  • Lawton instrumental activities of daily living scale
  • Lubben scale
  • male
  • Mini Mental State Examination
  • multicenter study
  • multiple cycle treatment
  • observational study
  • priority journal
  • prospective study
  • treatment duration
  • treatment response
  • weakness
  • age
  • clinical trial
  • pathophysiology
  • predictive value
  • procedures
  • Prostatic Neoplasms, Castration-Resistant
  • randomized controlled trial (topic)
  • very elderly
  • Age Factors
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents
  • Geriatric Assessment
  • Humans
  • Male
  • Predictive Value of Tests
  • Prospective Studies
  • Randomized Controlled Trials as Topic
  • Taxoids

Fingerprint Dive into the research topics of 'Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: The prospective observational scoop trial results'. Together they form a unique fingerprint.

  • Cite this

    Pepa, C. D., Cavaliere, C., Rossetti, S., Di Napoli, M., Cecere, S. C., Crispo, A., De Sangro, C., Rossi, E., Turitto, D., Germano, D., Iovane, G., Berretta, M., D'Aniello, C., Pisconti, S., Maiorino, L., Daniele, B., Gridelli, C., Pignata, S., & Facchini, G. (2017). Predictive Comprehensive Geriatric Assessment in elderly prostate cancer patients: The prospective observational scoop trial results. Anti-Cancer Drugs, 28(1), 104-109. https://doi.org/10.1097/CAD.0000000000000428